XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
Andreas Engert(University of Cologne), Auro del Giglio(Faculdade de Medicina do ABC), Heinz Lubenau(Technische Hochschule Mannheim), Y. Zyuzgin(Leningrad Regional Cancer Center), Laimonas Griškevičius(Vilnius University)
Cited by 76
Related Papers
Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications
|Photodiagnosis and Photodynamic Therapy|2005|910
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
|The Lancet|2022|407
The biology of cancer-related fatigue: a review of the literature
|Supportive Care in Cancer|2015|305
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
|Journal of Clinical Oncology|2012|261